3.4.2016 Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.

Slides:



Advertisements
Similar presentations
Uterine & Ovarian Cancer
Advertisements

بسم الله الرحمن الرحيم. Pelvic mass Dr.T Allameh MD.
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
Pelvic Masses & Ovarian Cancer. Differential diagnosis of pelvic masses Investigations and management Benign ovarian cysts Ovarian cancer.
Gynecologic Cancers Presented by: Michael Goodheart, MD Assistant Professor Gynecologic Oncology The University of Iowa Hospitals & Clinics Understanding,
Endometrial Cancer Tseng Jen-Yu 02/05/2007 Tseng Jen-Yu 02/05/2007.
Tim Broadhead Consultant Gynaecologist & Gynaecological Oncologist
SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®
Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.
Malignant Ovarian Tumors
Ovary.
22/10/1436. Addar Professor Gyneoncologist OB/GYN Dept. KKUH and College of Medicine MKing Saud University.
All Our Ovaries Ovarian Health Bulletin Board Submitted by Abby Hargreaves, RA, Hollins University.
Ovarian cancer….. in 15 minutes
Ovarian Cancer Awareness In the Community. Facts about Ovarian Cancer 80% of cases occur in women over th most common cancer in women Almost 7000.
Ovarian tumours.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Focus on Ovarian Cancer (Relates to Chapter 54, “Nursing Management: Female Reproductive Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc.,
Ovarian cysts in Primary Care. When to refer? Physiological/pathological Benign/malignant Surgical approach? Open or keyhole? Do I need to do anything?
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
SUMAYYA EBRAHIM GYNAECOLOGIST PARKLANE CLINIC JOHANNESBURG
Familial Ovarian Cancer Diane Stirling. Ovarian cancer in the UK 5th highest incidence of ovarian cancer. 4th most common cancer in women Risk of developing.
Ovarian Cancer National Alliance Ovarian Cancer: What All Women Need to Know.
Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
Ovarian Tumours Max Brinsmead MBBS PhD November 2014.
Fallopian Tube and Ovarian Malignancy Schwartz's Principles of Surgery Chapter 41. Gynecology.
BY DR. KHANSA IQBAL SENIOR REGISTRAR GYNAE UNIT-II.
Quang Truong Mr. Kashub 2nd Session
Ovarian Pathology for Undergraduates Max Brinsmead MB BS PhD November 2014.
Ovarian Cancer Research in Allied Health Erin Brewer.
Computed tomography scan of the abdomen shows a large cystic mass in the abdomen and pelvis without solid tissue or septations (measurement: 43×20×31-cm.
Management of ovarian cysts
Endometrial Carcinoma
‘I am menopausal and my abdomen is distending’
Ovarian Cancer Tumour Markers Brig Dilshad Ahmed Khan MBBS, MCPS, FCPS, FRC Path, PhD Head of Chem Pathology & Endocrinology dept AFIP, Rawalpindi.
OVARIAN CANCER RISK FACTORS Studies have found the following risk factors for ovarian cancer:  Family history of cancer: Women who have a mother, daughter,
Breast/ovary.  A 32-year-old Caucasian female presents to your office with a breast mass found to be malignant on biopsy. Ten years ago, she was diagnosed.
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan.
Ovarian cancer Karima salama.
Endometrial Cancer By Jessica Hall. Symptoms Unusual vaginal bleeding or discharge Difficult or painful urination Pain during intercourse Pain in the.
Dr. Saadeh Jaber OBGYN consultant Epidemiology Second most common gynecological cancer. >35, median 70 It accounts for deaths more than cancer of.
Gynecological Malignancies. Gynecologic malignancies account for 15% of all cancers in women. Gynecologic malignancies account for 15% of all cancers.
Ovarian Cancers In Pregnancy. Incidence Effect on Pregnancy Histologic Variations Clinical Variation Ovarian Cancers in Pregnancy.
Survivors Teaching Students: Saving Women’s Lives®
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
KARIMA SALAMA ENDOMETRIAL CANCER. Epidemiology Most common gynecological cancer in the developed countries, with an incidence of 12.9 per 100,000 women.
Consultant Obstetrician & Gynaecologist
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
By: Anthony, Sophia, Jessica, Terrance, and Sierra.
Mark Browning, M.D. ‘77 IUSME
Metastatic Tumors of Ovary. METASTATIC TUMOR FROM BREAST CANCER both ovaries replaced by pale, rather nodular tumor, with breast cancer cells arranged.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
The Elliott Breast Center * Baton Rouge, LA *
Ovarian Cancer aka “The disease that whispers” Statistics The average age when ovarian cancer is detected in women is 56.3 years. Less than 1 out of.
M.D. Browning, M.D. ‘77.  Most Common Cancer of Female Reproductive System  60,000/year with 10,000 deaths  Normal Cells in the Endometrium.
Cancer Education Slides
Screening for Ovarian Cancer
Ovarian Cancer Screening and Diagnosis
Dr . Saadeh Jaber OBGYN consultant 2010
OVARIAN CANCER qpt
Screening for Ovarian Cancer
Male and Female Reproductive Health Concerns
Survivors Teaching Students: Saving Women’s LivesSM
بسم الله الرحمن الرحيم.
Ovarian Cancer-Route to Diagnosis
Ovarian Cancer Ovarian Cancer only affects women.
Prophylactic Oophorectomy
Presentation transcript:

Mark Browning, M.D. IUSME

 22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage

 Epithelial Cancer 90% of Cases  Surface of Ovary or Special Cells in Fallopian Tubes  High Grade Serous Tumors  Low Grade Serous Tumors  Germ Cell Tumor  Stromal Cell Tumor

 Usually presents with advanced disease  ¾ have disease beyond the ovary at diagnosis  Pelvic exams are helpful in diagnosing large masses  Premenopausal adnexal mass usually a cyst that regresses over time (7% are cancer)  Postmenopausal adnexal mass is worrisome (30% are cancer)

 95% of women DO report symptoms.  Symptoms can be vague and not gynecologic:  Abdominal bloating  Swollen abdomen  Fatigue  Diarrhea or constipation  Urinary symptoms  Abdominal/pelvic pain  Menstrual irregularities

 Spread by direct exfoliation of cells onto peritoneal surface/cavity  Most common mode of spread  Follow path of peritoneal fluid circulation into pericolic gutter and hemidiaphragm (develop a pleural effusion)  Peritoneal mets/adhesions

 Pelvic Exam, Transvaginal Ultrasound, CA 125  CT Scan, MRI, PET  Biopsy

 Surgical staging is mandatory  CA-125 is non-specific marker  AFP and b-HCG if suspect germ cell tumor (younger woman)

 Adenocarcinomas  Primary peritoneal carcinoma  Germ Cell Tumors  Rare  Low malignant potential (LMP)  “borderline tumors”  Single ovary, confined, younger age, pre- menopausal

 Salpingo-oophorectomy  Hysterectomy  Lymph Node Dissection  Omentectomy  Cytoreductive/Debulking Surgery  Chemo…Adjuvant…Neoadjuvant  Chemo for Recurrence

 Ovarian cancer originates from the cells that cover the ovary (epithelium).  Ovarian epithelium represents < 1% of the ovary.

 Women who carry a known mutation that predisposes to ovarian cancer (BRCA gene mutation)  Women who have a family history of ovarian or breast cancer  These women should be followed closely (CA125, gynecologic exam and ultrasound)  These women should consider removal of ovaries (oophorectomy) preventively.

 559 women, carriers of BRCA 1 or women surgery: 6 diagnosed with stage 1 ovarian cancer 2 developed primary peritoneal cancer 292 no surgery: 58 developed ovarian cancer Risk reduction: 96% (Rebbeck, NEMJ, 2002)

 Family history and parity are most impt risk factors  BRCA-1 is a strong risk factor (50% risk)  BRCA-2 also a risk factor, but much less so  Lynch II syndrome (DNA mismatch repair defect): HNPCC, ovarian, breast, endometrial ca  Prophylactic oophorectomy reduces risk 96%  Incessant ovulation hypothesis: risk decreases with decreasing ovulation  Use of OCP that suppress ovulation reduces lifetime risk by as much as 50%